TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

FTC challenge to Edwards JenaValve acquisition could delay FDA approval
Edwards Lifesciences asked the U.S. Federal Trade Commission (FTC) this week to dismiss the complaint against the company's acquisition of JenaValve this week. A healthcare market analysis firm also said the FTC actions will likely impact the timing of an FDA clearance of the Trilogy heart valve.
TAVR in patients with bicuspid aortic valve stenosis: Does device type matter?
More and more care teams are treating BAV stenosis with TAVR instead of surgical aortic valve replacement. Self-expanding and balloon-expandable valves appear to have their own benefits—as well as their own risks.
Hemodynamic deterioration 1 year after TAVR found in 6% of patients
Hemodynamic valve deterioration after one year was more common in patients with a small aortic annulus. In fact, receiving a larger valve was linked to a “protective” quality that appeared to help keep the risk of such complications to a minimum.
FTC challenges ‘anticompetitive’ TAVR acquisition
The FTC is working to stop Edwards Lifesciences from completing its acquisition of JenaValve. Edwards, however, is not backing down.
Exploring the value of same-day permanent pacemaker implantation after TAVR
Temporary pacemakers are typically used for at least 24 hours before care teams consider implanting a permanent device. New research out of Canada suggests it may make sense in certain scenarios to go straight to the permanent pacemaker.

No contrast transcatheter aortic valve replacement

New ‘zero-contrast’ TAVR technique shows promise in pilot study

Researchers think this new technique could be beneficial for patients presenting with both severe symptomatic aortic stenosis and chronic kidney disease.

The Edwards Lifesciences Sapien transcatheter aortic valve replacement (TAVR) device in a heart model used to show patients how the device works.

Balloon-expandable valves deliver better short-term TAVR outcomes than self-expandable valves

A new meta-analysis, published in Frontiers in Cardiovascular Medicine, focused on data from nearly 3,000 patients with severe symptomatic aortic stenosis.

elderly patient using virtual reality TAVR transcatheter aortic valve replacement

Virtual reality during TAVR: Distracting patients linked to key benefits

When patients wear VR glasses during transcatheter aortic valve replacement, they say it helps time go by more quickly and reduces anxiety.

How to encourage shared decision-making when treating aortic stenosis

Diagnosing, treating and managing aortic stenosis is often a challenging task, especially when the patient has a long life expectancy. Shared decision-making can make a significant impact, helping ensure the patient's values and preferences are taken into consideration.

A TAVR procedure being performed at Northwestern Medicine in Chicago. These structural heart procedures require a team approach.

Heart damage after TAVR: Follow-up imaging helps cardiologists anticipate problems

While cardiac damage reverses in many patients following treatment, it can actually continue to get worse in others.

Rethinking SAVR in the TAVR era: New Cleveland Clinic study explores data from nearly 3,500 patients

SAVR may be even safer for low-risk patients than previously believed, according to new research published in the Journal of Thoracic and Cardiovascular Surgery. What does this tell us about patient care going forward?

Cardiologists perform world’s first TAVR with new ultra-low profile valve

The 88-year-old patient was originally not seen as a viable candidate for TAVR or surgery.

The Wattson temporary pacing guidewire from Teleflex

FDA clears new guidewire used for valve delivery and ventricular pacing during TAVR, BAV procedures

The device, now on display at TVT 2023 in Phoenix, is scheduled to begin hitting the market in the months ahead.

TAVR

FTC challenge to Edwards JenaValve acquisition could delay FDA approval

TAVR in patients with bicuspid aortic valve stenosis: Does device type matter?

Hemodynamic deterioration 1 year after TAVR found in 6% of patients

FTC challenges ‘anticompetitive’ TAVR acquisition

Exploring the value of same-day permanent pacemaker implantation after TAVR